{"id":"W2582709627","doi":"10.1016/s1474-4422(16)30399-4","title":"Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"Italfarmaco; Baxalta; European Commission; Cytokinetics; Biogen; GlaxoSmithKline","keywords":"Medicine; Placebo; Amyotrophic lateral sclerosis; Internal medicine; Clinical trial; Adverse effect; Clinical endpoint; Physical therapy; Disease; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008315441,0.0002463654,0.001396974,0.0001260643,0.00022583,0.00005239177,0.0004668229,0.0001631216,0.00007784797],"category_scores_gemma":[0.0003301156,0.0001343828,0.0001081201,0.00009254445,0.0006367828,0.0001163116,0.00020575,0.0006861864,0.00001022259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002426738,"about_ca_system_score_gemma":0.00008075524,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001661041,"about_ca_topic_score_gemma":0.00004845949,"domain_scores_codex":[0.9976221,0.0004075248,0.0005646426,0.0004187805,0.0004061115,0.0005808899],"domain_scores_gemma":[0.9979551,0.0003873901,0.0003833967,0.001035833,0.0001024239,0.0001358007],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9753796,0.0006361782,0.02144002,0.00002697347,0.0001567526,0.00003483037,0.0001363208,0.0000268713,0.0003890028,0.00005991056,0.00004141232,0.001672097],"study_design_scores_gemma":[0.6693231,0.00430351,0.3258518,0.00004477932,0.00009207494,0.000008365461,9.004153e-7,0.0001795568,0.00001993723,0.00002180018,0.00007230923,0.00008192724],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868432,0.0000627894,0.000004007772,0.007647001,0.0001492666,0.004816914,0.00001328554,0.00002538128,0.0004381792],"genre_scores_gemma":[0.9985948,0.000199454,0.00001818346,0.0005089296,0.0003691326,0.0001822235,0.00001404625,0.00003277499,0.00008051797],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3060566,"threshold_uncertainty_score":0.5479974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0582750514239321,"score_gpt":0.3281753930159591,"score_spread":0.269900341592027,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}